Research
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e1369 (Published 12 March 2012) Cite this as: BMJ 2012;344:e1369Data supplement
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Appendix 1: Search strategy
- Data Supplement - Appendix 2: Summary of risk of bias assessment
- Data Supplement - Appendix 3: Funnel plot based on mean difference for change in HbA1c and study precision
- Data Supplement - Appendix 4: Summary of findings of main analysis and sensitivity analyses comparing DPP-4 inhibitors with active comparators on change in HbA1c from baseline
Related articles
- Editorial Published: 12 March 2012; BMJ 344 doi:10.1136/bmj.e1213
- Paper Published: 13 September 1997; BMJ 315 doi:10.1136/bmj.315.7109.629
- Research Methods & Reporting Published: 10 February 2011; BMJ 342 doi:10.1136/bmj.d549
- Editorial Published: 17 March 2011; BMJ 342 doi:10.1136/bmj.d1354
- Correction Published: 20 July 2012; BMJ 345 doi:10.1136/bmj.e4959
- Correction Published: 26 July 2012; BMJ 345 doi:10.1136/bmj.e5129
- Research Published: 15 April 2014; BMJ 348 doi:10.1136/bmj.g2366
- Letter Published: 24 April 2012; BMJ 344 doi:10.1136/bmj.e2917
- Letter Published: 24 April 2012; BMJ 344 doi:10.1136/bmj.e2922
- Research Published: 03 May 2016; BMJ 353 doi:10.1136/bmj.i2231
See more
- Type 1 diabetes: Randox removes adverts after claims that it was using fear to sell genetic testBMJ March 25, 2024, 384 q744; DOI: https://doi.org/10.1136/bmj.q744
- FDA approves first over-the-counter blood glucose monitor for diabetesBMJ March 11, 2024, 384 q611; DOI: https://doi.org/10.1136/bmj.q611
- US food manufacturer can say that eating yogurt reduces risk of type 2 diabetes, says FDABMJ March 06, 2024, 384 q569; DOI: https://doi.org/10.1136/bmj.q569
- Scarlett McNally: Preventing obesity is different from curing it—and even more urgentBMJ January 23, 2024, 384 q134; DOI: https://doi.org/10.1136/bmj.q134
- Artificial pancreases for type 1 diabetes: Better access is “watershed moment”—but delivery is keyBMJ January 23, 2024, 384 q102; DOI: https://doi.org/10.1136/bmj.q102
Cited by...
- Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes
- Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
- Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy
- Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
- Discrepancies between ClinicalTrials.gov recruitment status and actual trial status: a cross-sectional analysis
- Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study
- Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and hospital-treated infections in patients with type 2 diabetes: a Danish nationwide population-based cohort study
- Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
- Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know
- Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
- Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
- DPP4 in Cardiometabolic Disease: Recent Insights From the Laboratory and Clinical Trials of DPP4 Inhibition
- Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
- Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On!
- The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
- Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
- Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations
- Insulin resistance and cancer: the role of insulin and IGFs
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- No better than less expensive drugs
- Authors' reply to Scheffel and Schaan
- Report was overpositive about their benefits
- Gliptins vs. the Alternatives for Type 2 Diabetes
- The role of dipeptidyl peptidase-4 inhibitors